Kinase Inhibitor [EPC]

320686 reported adverse events

Drugs of this class: SIROLIMUS EVEROLIMUS PALBOCICLIB AXITINIB LAROTRECTINIB PRALSETINIB ABEMACICLIB ACALABRUTINIB AFATINIB AVAPRITINIB BRIGATINIB

These side effects are most commonly reported by patients taking drugs of the Kinase Inhibitor [EPC] class:

# Side effect Count
0 DEATH 35846
1 FATIGUE 28290
2 DIARRHOEA 26535
3 NAUSEA 18851
4 OFF LABEL USE 17272
5 RASH 13196
6 MALIGNANT NEOPLASM PROGRESSION 12136
7 ASTHENIA 11682
8 DECREASED APPETITE 11636
9 DYSPNOEA 11424
See all common reactions for Kinase Inhibitor [EPC]

Drugs of the Kinase Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EGFR GENE MUTATION 191 0.8565
1 CYTOGENETIC ANALYSIS ABNORMAL 335 0.5226
2 NEOPLASM PROGRESSION 9346 0.4399
3 ACQUIRED GENE MUTATION 309 0.4055
4 TRANSPLANT DYSFUNCTION 488 0.4013
5 CHRONIC MYELOID LEUKAEMIA RECURRENT 132 0.3882
6 NON-SMALL CELL LUNG CANCER 738 0.3230
7 HEPATOCELLULAR CARCINOMA 1702 0.3148
8 TUMOUR MARKER INCREASED 842 0.3127
9 HAEMATOCRIT ABNORMAL 253 0.3048
See all enriched reactions for Kinase Inhibitor [EPC]